# nference

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nference

- Industry: Software
- Headquarters: Cambridge, US
- Website: www.nference.ai
- Total disclosed funding: $109M
- Latest round: Series C (Dec 15, 2020)
- Investors on record: 4

## About

nference, Inc. is a US-based software company specializing in transforming real-world healthcare data into actionable insights through advanced clinical AI technology, enhancing decision-making in healthcare settings.Founded in 2013 in Cambridge, US, nference, Inc. operates as a software company focused on leveraging healthcare data analytics. The company has raised a total of USD 54.80 mn through 5 deals, with the most recent being a Series C funding round in December 2020, led by Matrix Capital Management. The CEO, Murali Aravamudan, is one of the co-founders, who has a history of engagement in technology startups.nference specializes in transforming real-world healthcare data into actionable insights through its advanced clinical AI platform. The core product offerings include a robust suite of data analytics solutions designed to harmonize disparate healthcare data sources, including radiology images, ECG waveforms, clinical notes, and more. These tools utilize proprietary algorithms and machine learning techniques to extract meaningful variables from unstructured data, enabling healthcare providers and researchers to enhance clinical decision-making and improve patient outcomes. The company's solutions serve a diverse clientele, including healthcare systems, research institutions, and life sciences companies across multiple geographical markets, including North America, Europe, and Asia. By focusing on critical therapeutic areas such as oncology, cardiology, neurology, and immunology, nference addresses the pressing need for accelerated research and development in these fields.nference generates revenue primarily through strategic partnerships and subscription-based models that cater to healthcare systems and life sciences organizations. The company’s transactions typically involve long-term collaborations where clients gain access to its AI-powered analytics platform, which aids in clinical data management and research initiatives. Clients may subscribe to various tiers of service, tailored to their specific needs, which include access to unique clinical biomarkers and data management tools. Each customer engagement may vary in scale and complexity, reflecting the specific requirements of the healthcare institutions or research entities involved. Through these business transactions, nference positions itself as a vital partner in the pursuit of innovative health solutions and evidence-based medical practices.nference, Inc. plans to utilize the recent Series C funding of USD 54.80 mn, secured on December 15, 2020, to enhance its product offerings and expand into new markets. The company is developing new AI tools designed to further streamline healthcare data analytics, with a launch anticipated in 2022. Additionally, nference aims to penetrate European and Asian markets more deeply by 2023, targeting healthcare systems and institutions that can benefit from improved clinical decision-making and data management.

## Funding rounds

- Series C, Dec 15, 2020, $55M — Matrix Partners, Mayo Clinic Ventures, Matrix Capital Management, NTT Venture Capital
- Series B, Nov 2, 2020 — NTT Venture Capital
- Series B, Jul 23, 2019, $40M — Mayo Clinic Ventures, NTT Venture Capital
- Series A, Jun 6, 2018, $11M — Matrix Partners, Matrix Capital Management
- Seed, Jun 29, 2017, $3.2M — Matrix Partners, Matrix Capital Management

## Investors

- Matrix Partners (https://capitalatlas.ai/funds/matrix-partners) — Seed, Series A, Series C
- Matrix Capital Management — Seed, Series A, Series C
- Mayo Clinic Ventures (https://capitalatlas.ai/funds/mayo-clinic-ventures) — Series B, Series C
- NTT Venture Capital (https://capitalatlas.ai/funds/ntt-venture-capital) — Series B, Series C